FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
    Research/Science 2/22/2026

    From the encyclopedia
    PP405 →

    mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    Clascoterone →

    Topical androgen-receptor blocker, approved as an acne cream

    At a glance
    In this educational post the tone is 😐 neutral.

    Other terms

    The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community Thoughts on the future of pp405?

       43 upvotes 10 months ago
      PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

      community Does anyone else feel that the hype for PP405 has gone?

      in Chat  25 upvotes 4 months ago
      The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.

      community Are these new hair loss treatments ever gonna release?

       43 upvotes 6 months ago
      Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.

      community Most Promising Future Hair Loss Treatments In 2026

       83 upvotes 2 weeks ago
      Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.

    Related Research

    6 / 6 results